All In Biotech

NDA 020041 · Otsuka Icu Medcl

Aminosyn Ii 15% In Plastic Container

Amino Acids · Injection · Amino Acid

Last checked: Nov 19, 2026Latest source record: Apr 27, 2007 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1991

Dec 19, 1991

Approved uses

1

Original approval plus efficacy supplements

Registered trials

30,323

6,603 Phase 3, 2,682 recruiting

FAERS reports

4

2 serious, 0 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

Pharmacy Bulk Package – Not For Direct Infusion.

What it is approved for

From the label in effect Nov 2, 2025.

INDICATIONS AND USAGE Aminosyn II, Sulfite-Free, (an amino acid injection) infused with dextrose by peripheral vein infusion is indicated as a source of nitrogen in the nutritional support of patients with adequate stores of body fat, in whom, for short periods of time, oral nutrition cannot be tolerated, is undesirable, or inadequate. SUPPLEMENTAL ELECTROLYTES, IN ACCORDANCE WITH THE PRESCRIPTION OF THE ATTENDING PHYSICIAN, MUST BE ADDED TO AMINOSYN II SOLUTIONS WITHOUT ELECTROLYTES. Aminosyn II can be administered peripherally with dilute (5 to 10%) dextrose solution and I.V. fat emulsion as a source of nutritional support. This form of nutritional support can help to preserve protein and reduce catabolism in stress conditions where oral intake is inadequate. Aminosyn II is also indicated for central vein infusion to prevent or reverse negative nitrogen balance in patients where the alimentary tract, by the oral, gastrostomy or jejunostomy route cannot or should not be used and gastrointestinal absorption of protein is impaired.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Dec 19, 1991 Original approval · Type 3 - New Dosage Form
1 products under this application
  • AMINOSYN II 15% IN PLASTIC CONTAINER · AMINO ACIDS 15% (15GM/100ML) · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Amino Acids" as an intervention, any sponsor and status, largest first.

All 30,323 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • arthralgia1
  • furuncle1
  • pain in extremity1
  • product colour issue1
  • product dispensing error1
  • product odour abnormal1
  • product preparation error1
  • product quality issue1
  • product supply issue1
  • rheumatoid arthritis1
  • uterine disorder1

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20141
20151
20182

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

  • Current · updated Nov 17, 2026

    Aminosyn II 15% In Plastic Container, Injection, 0.15 (NDC 0990-7171-17). This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 3,551 on PubMed

Sponsor: Otsuka

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.